OBJECTIVE: Determine the probability of a more than 1-year remission after failure of a second drug in children prospectively followed from initial diagnosis of epilepsy and then from time of second drug failure. Identify prognostic factors for remission after second drug failure. METHODS: Of 613 children, 128 did not respond favorably to 2 drugs, had a trial of at least a third drug (median, 3), and were followed for more than 1 year (median, 10.1 years) since second drug failure. Product limit and proportional hazards techniques were used to analyze predictors of any 1-year remission (Rem1) and 1- and 3-year remission at last contact (Rem1/3-LC). RESULTS: Seventy-three patients (57%) had a remission. Repeated remissions and relapses were common. Only 48 (37.5%) achieved Rem1-LC and 28 (23%) Rem3-LC. Idiopathic epilepsy (Rem1: rate ratio [RR], 3.64, p < 0.0001; Rem1-LC: RR, 2.57, p = 0.008) and seizure frequency (Rem1: RR, 0.76, p = 0.003; Rem1-LC: RR, 0.82, p = 0.04 per increase in category) were the most robust predictors. Symptomatic cause was the only correlate of Rem3-LC. Remission before second drug failure did not predict remission after second drug failure. INTERPRETATION: Remission after second drug failure is common but often temporary. Children who have not responded to two appropriate drugs should be carefully evaluated to maximize therapy and possibly considered for more aggressive treatments.
OBJECTIVE: Determine the probability of a more than 1-year remission after failure of a second drug in children prospectively followed from initial diagnosis of epilepsy and then from time of second drug failure. Identify prognostic factors for remission after second drug failure. METHODS: Of 613 children, 128 did not respond favorably to 2 drugs, had a trial of at least a third drug (median, 3), and were followed for more than 1 year (median, 10.1 years) since second drug failure. Product limit and proportional hazards techniques were used to analyze predictors of any 1-year remission (Rem1) and 1- and 3-year remission at last contact (Rem1/3-LC). RESULTS: Seventy-three patients (57%) had a remission. Repeated remissions and relapses were common. Only 48 (37.5%) achieved Rem1-LC and 28 (23%) Rem3-LC. Idiopathic epilepsy (Rem1: rate ratio [RR], 3.64, p < 0.0001; Rem1-LC: RR, 2.57, p = 0.008) and seizure frequency (Rem1: RR, 0.76, p = 0.003; Rem1-LC: RR, 0.82, p = 0.04 per increase in category) were the most robust predictors. Symptomatic cause was the only correlate of Rem3-LC. Remission before second drug failure did not predict remission after second drug failure. INTERPRETATION: Remission after second drug failure is common but often temporary. Children who have not responded to two appropriate drugs should be carefully evaluated to maximize therapy and possibly considered for more aggressive treatments.
Authors: Anne T Berg; Barbara G Vickrey; Francine M Testa; Susan R Levy; Shlomo Shinnar; Frances DiMario; Susan Smith Journal: Ann Neurol Date: 2006-07 Impact factor: 10.422
Authors: Howard L Weiner; Chad Carlson; Emily B Ridgway; Charles M Zaroff; Daniel Miles; Josiane LaJoie; Orrin Devinsky Journal: Pediatrics Date: 2006-05 Impact factor: 7.124
Authors: Willem F M Arts; Oebele F Brouwer; A C Boudewijn Peters; Hans Stroink; Els A J Peeters; Paul I M Schmitz; Cees A van Donselaar; Ada T Geerts Journal: Brain Date: 2004-06-16 Impact factor: 13.501
Authors: Hyunmi Choi; Gary A Heiman; Heidi Munger Clary; Mill Etienne; Stanley R Resor; W Allen Hauser Journal: Epilepsy Res Date: 2010-12-21 Impact factor: 3.045
Authors: Brian Callaghan; Malka Schlesinger; William Rodemer; John Pollard; Dale Hesdorffer; W Allen Hauser; Jacqueline French Journal: Epilepsia Date: 2011-01-26 Impact factor: 5.864
Authors: Anne T Berg; Gary W Mathern; Richard A Bronen; Robert K Fulbright; Francis DiMario; Francine M Testa; Susan R Levy Journal: Brain Date: 2009-07-28 Impact factor: 13.501